Dr. Willmar Schwabe

CompanyGermanyFounded 1866

Dr. Willmar Schwabe develops one asset, in phase 3 (Extract of Ginkgo Biloba Leaves in cognitive impairment). Mostly other; based in Germany, founded in 1866.

1
Asset
Furthest stage: Phase 3; 1
Trial: 2
Signals

Pipeline

1

Extract of Ginkgo Biloba Leaves
Phase 3, Other, cognitive impairment, ischemic stroke hospitalized

Full company profiles: pipeline, trials, funding and people.

In the full profile

Trials1
Signals3
Similar companies6

Papers

Miquelianin and spiraeoside from Filipendula ulmaria mitigate α-synuclein accumulation in C.elegans and reduce the expression of neuroinflammatory cytokines in human microglia
Frontiers in pharmacology, Feb 27, 2026
Balance Training With Vibrotactile Neurofeedback and Ginkgo Biloba Extract in Age-Related Vertigo
Frontiers in neurology, Dec 18, 2021
Moderately aged OFA rats as a novel model for mild age-related alterations in learning and memory
Brain and cognition, Sep 17, 2021
Effects of Ginkgo biloba extract EGb 761® on cognitive control functions, mental activity of the prefrontal cortex and stress reactivity in elderly adults with subjective memory impairment - a randomized double-blind placebo-controlled trial
Human psychopharmacology, May 6, 2016